StudyFinder

MT2021-08: Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults with Hematological Malignancies

Recruiting

The research aspect of this trial is the use of a new machine to remove specific lymphocytes from the donor’s peripheral blood stem cells (PBSCs). This is called T cell receptor alpha/beta T cell depletion. This machine does such a good job at removing the unwanted donor T cells, and as a result we think patients will need fewer drugs to suppress their immune system.

I'm interested

Male or Female
Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• hematological cancer needing stem cell transplant
• 60 years old or younger
Exclusion Criteria:

• pregnant or breast feeding
• active infection
• positive for HIV, Hepatitis B or C
• brain metastasis

Drug: Busulfan, Drug: Fludarabine, Drug: Levetiracetam, Drug: Melphalan, Drug: Rituximab

Cancer

Hematologic Malignancy, Leukemia, Stem Cell Transplant, Clinics and Surgery Center (CSC)

Andrea Middendorf - midde019@umn.edu
Margaret MacMillan, MD
PHASE2
STUDY00016450
See this study on ClinicalTrials.gov

Back